Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record.

A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome

YU, MIHAE, TOMASA, GRACE · 1993 · Critical Care Medicine

Abstract

OBJECTIVE: To determine if ketoconazole, a thromboxane A2 synthetase inhibitor, given within the first 24 hrs after diagnosis and arrival in the intensive care unit (ICU) would decrease the frequency of adult respiratory distress syndrome in the septic patient population. DESIGN: Prospective, randomized, double-blind, placebo-controlled study. SETTING: Twelve-bed, surgical ICU in a university-affiliated hospital. PATIENTS: Fifty-four consecutive patients admitted to the surgical ICU with the diagnosis of sepsis composed the study sample. Sepsis was defined as including two or more of the following signs in a patient with a systolic blood pressure of < 80 mm Hg or a systemic vascular resistance of < 800 dyne.sec/cm5: a) temperature > or = 39 degrees C or < or = 35 degrees C; b) white blood cell count of > 12,000 leukocytes, or < or = 4000 leukocytes/microL, or > or = 20% immature cells; c) positive blood culture; d) known or strongly suspected source of infection from which a known pathogen was cultured. INTERVENTIONS: Patients were randomized to receive either ketoconazole (400 mg) or placebo in a double-blind fashion as early as possible and in < 24 hrs after surgical ICU admission or after the diagnosis of sepsis was established. MEASUREMENTS AND MAIN RESULTS: Adult respiratory distress syndrome (ARDS) was diagnosed if the following criteria were met: a) intrapulmonary shunt of > 20%, or a PaO2/FIO2 ratio of < 150 requiring ventilatory support for > 48 hrs; b) pulmonary artery occlusion pressure of < 18 mm Hg and no clinical signs of heart failure; and c) diffuse infiltrates on chest radiograph. Treatment resulted in significant (p = .002) reduction in the frequency of ARDS compared with the placebo group, 64% vs. 15% in the ketoconazole treated group. The mortality rate was also reduced from 39% in the placebo group to 15% in the ketoconazole group (p = .05). A statistically significant reduction in ventilator and ICU days was not achieved. CONCLUSIONS: Ketoconazole (400 mg through the gastrointestinal tract) given early in the septic course may prevent ARDS and decrease the mortality rate in high-risk, septic patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00003246-199311000-00010

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 158

Metadata

Authors
YU, M., & TOMASA, G.
Venue
Critical Care Medicine
Published
1993-11
Volume
21
Issue
11
Pages
1635-1641
ISSN
0090-3493 (ISSN-L)
OpenAlex
W2063951746
Cited by
158
References
0
FWCI
9.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. https://app.cochat.ai/papers/10.1097/00003246-199311000-00010
The paper
YU, M., & TOMASA, G. (1993). A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine. https://doi.org/10.1097/00003246-199311000-00010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.